All NewsFDA BriefsOncology IconsSpecial ReportsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision MedicineSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2 Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE
Advertisement

Relapsed and Refractory CLL with Javier Pinilla-lbarz, MD, PhD and Paul Barr, MD: Case 2

home / case-based-peer-perspectives / relapse-refractory-cll-case2

Relapsed and Refractory CLL with Javier Pinilla-lbarz, MD, PhD and Paul Barr, MD

Javier Pinilla-Ibarz, MD, PhD: Relapse Following Purine Analog Therapy

EP. 1: Javier Pinilla-Ibarz, MD, PhD: Relapse Following Purine Analog Therapy

September 26th 2015

Watch

Javier Pinilla-Ibarz, MD, PhD: Treatment Options for Patients With Previously Treated CLL

EP. 2: Javier Pinilla-Ibarz, MD, PhD: Treatment Options for Patients With Previously Treated CLL

September 26th 2015

Watch

Javier Pinilla-Ibarz, MD, PhD: Bendamustine/Rituximab Therapy

EP. 3: Javier Pinilla-Ibarz, MD, PhD: Bendamustine/Rituximab Therapy

September 26th 2015

Watch

Javier Pinilla-Ibarz, MD, PhD: Options to Prolong Survival

EP. 4: Javier Pinilla-Ibarz, MD, PhD: Options to Prolong Survival

September 26th 2015

Watch

Javier Pinilla-Ibarz, MD, PhD: Phase III Data to Support Usage of Bruton's TKIs

EP. 5: Javier Pinilla-Ibarz, MD, PhD: Phase III Data to Support Usage of Bruton's TKIs

September 26th 2015

Watch

Paul Barr, MD: Treatment Options for Patients With Previously Treated CLL

EP. 6: Paul Barr, MD: Treatment Options for Patients With Previously Treated CLL

September 26th 2015

Watch

Paul Barr, MD: Bendamustine/Rituximab Therapy

EP. 7: Paul Barr, MD: Bendamustine/Rituximab Therapy

September 26th 2015

Watch

Paul Barr, MD: Options to Prolong Survival

EP. 8: Paul Barr, MD: Options to Prolong Survival

September 26th 2015

Watch

Paul Barr, MD: Relapse Following Purine Analog Therapy

EP. 9: Paul Barr, MD: Relapse Following Purine Analog Therapy

September 26th 2015

Watch

Paul Barr, MD: Phase III Data to Support Usage of Bruton's TKIs

EP. 10: Paul Barr, MD: Phase III Data to Support Usage of Bruton's TKIs

September 26th 2015

Watch

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2024 MJH Life Sciences

All rights reserved.